Biology Reference
In-Depth Information
25 Nissenson AR (1992) Epoetin and cognitive function.
Am J Kidney Dis
20: 21-24
26 Schaefer RM, Kokot F, Heidland A (1989) Impact of recombinant erythropoietin on sexual func-
tion in hemodialysis patients.
Contrib Nephrol
76: 273-281
27 Bommer J, Kugel M, Schwobel B, Ritz E, Barth HP, Seelig R (1990) Improved sexual function
during recombinant human erythropoietin therapy.
Nephrol Dial Transplant
5:204-207
28Gladziwa U, Dakshinamurty KV, Mann H, Sieberth HG (1992) Pregnancy in a dialysis patient
under recombinant human erythropoietin.
Clin Nephrol
37: 215
29 Kokot F, Wiecek A, Grzeszczak W, Klepacka J, Klin M, Lao M (1989) Influence of erythropoietin
treatment on endocrine abnormalities in haemodialyzed patients.
Contrib Nephrol
76:257-270
30 Barany P, Fehrman I, Godoy C (1992) Long-term effects on lymphocytotoxic antibodies and
immune reactivity in hemodialysis patients treated with recombinant human erythropoietin.
Clin
Nephrol
37: 90-96
31 Sennesael JJ, Van der Niepen P, Verbeelen DL (1991) Treatment with recombinant human ery-
thropoietin increases antibody titers after hepatitis B vaccination in dialysis patients.
Kidney Int
40: 121-128
32 Veys N, Vanholder R, Ringoir S (1992) Correction of deficient phagocytosis during erythropoietin
treatment in maintenance hemodialysis patients.
Am J Kidney Dis
19: 358-363
33 De Marchi S, Cecchin E, Villalta D, Sepiacci G, Santini G, Bartoli E (1992) Relief of pruritus and
decreases in plasma histamine concentrations during erythropoietin therapy in patients with ure-
mia.
N Engl J Med
326: 969-974
34 Raine AE, Roger SD (1991) Effects of erythropoietin on blood pressure.
Am J Kidney Dis
18:
76-83
35 Edmunds ME, Walls J, Tucker B, Baker LR, Tomson CR, Ward M, Cunningham J, Moore R,
Winearls CG (1989) Seizures in haemodialysis patients treated with recombinant human erythro-
poietin.
Nephrol Dial Transplant
4: 1065-1069
36 Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin
DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac
disease who are receiving hemodialysis and epoetin.
N Engl J Med
339: 584-590
37 Granolleras C, Leskopf W, S haldon S, Fourcade J (1991) Experience of pain after subcutaneous
administration of different preparations of recombinant human erythropoietin: A randomized,
double-blind crossover study.
Clin Nephrol
36: 294-298
38 Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo
V, Teyssandier I et al. (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients
treated with recombinant erythropoietin.
N Engl J Med
346: 469-475
39 Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett
RW, Jolliffe LK, Dower WJ (1996) Small peptides as potent mimetics of the protein hormone ery-
thropoietin.
Science
273:458-464
40 Osada S, Ebihara I, Setoguchi Y, Ta kahashi H, Tomino Y, Koide H (1999) Gene therapy for renal
anemia in mice with polycystic kidney using an adenovirus vector encoding the human erythro-
poietin gene.
Kidney Int
55: 1234-1240
